Pharmaceutical

Bionomics to advance non-SSRI PTSD candidate to Phase III

Bionomics plans to meet with the FDA following positive topline data from the Phase IIb ATTUNE trial of the post-traumatic stress disorder (PTSD) drug BNC210.

Mar 22, 2024 - 00:00
Bionomics to advance non-SSRI PTSD candidate to Phase III
Bionomics plans to meet with the FDA following positive topline data from the Phase IIb ATTUNE trial of the post-traumatic stress disorder (PTSD) drug BNC210.
Read the original article

Tags:

Previous Article

Molecular glues are the latest craze in pharma research, but what are they?

Next Article

Capstan secures $175m Series B funds for CAR-T therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Having a child with complex medical needs is hard enough. Navigating the health care system makes it worse

Opinion: Having a child with complex medical needs is h...

Dec 7, 2023

STAT+: Novo Nordisk enlists two Flagship biotechs to develop obesity, MASH drugs

STAT+: Novo Nordisk enlists two Flagship biotechs to de...

Jan 4, 2024

Opinion: The mifepristone debacle is just the latest blow in an ongoing assault on the FDA’s authority

Opinion: The mifepristone debacle is just the latest bl...

Apr 11, 2023